Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.65
BIOC's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: 2.65 )
BIOC' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 2.65

Equity to Asset 0.52
BIOC's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: 0.52 )
BIOC' s 10-Year Equity to Asset Range
Min: -18.63   Max: 0.83
Current: 0.52

-18.63
0.83
Z-Score: -14.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -11085.71
BIOC's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: -11085.71 )
BIOC' s 10-Year Operating margin (%) Range
Min: -1227100   Max: -5928.36
Current: -11085.71

-1227100
-5928.36
Net-margin (%) -13731.63
BIOC's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: -13731.63 )
BIOC' s 10-Year Net-margin (%) Range
Min: -1362900   Max: -6890.3
Current: -13731.63

-1362900
-6890.3
ROA (%) -239.83
BIOC's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: -239.83 )
BIOC' s 10-Year ROA (%) Range
Min: -694.81   Max: -659.5
Current: -239.83

-694.81
-659.5
ROC (Joel Greenblatt) (%) -2836.55
BIOC's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: -2836.55 )
BIOC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3360.96   Max: -1614.63
Current: -2836.55

-3360.96
-1614.63
» BIOC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2012

BIOC Guru Trades in Q2 2012

Jim Simons 483,500 sh (-1.49%)
Chuck Royce 695,891 sh (-12.97%)
» More
Q3 2012

BIOC Guru Trades in Q3 2012

Jim Simons 487,800 sh (+0.89%)
Chuck Royce 680,791 sh (-2.17%)
» More
Q4 2012

BIOC Guru Trades in Q4 2012

Jim Simons 491,500 sh (+0.76%)
Chuck Royce 680,791 sh (unchged)
» More
Q1 2013

BIOC Guru Trades in Q1 2013

Chuck Royce Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BIOC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.70
BIOC's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: 1.70 )
BIOC' s 10-Year P/B Range
Min: 1.26   Max: 3.91
Current: 1.7

1.26
3.91
EV-to-EBIT -0.37
BIOC's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: -0.37 )
BIOC' s 10-Year EV-to-EBIT Range
Min: -1.1   Max: 0.4
Current: -0.37

-1.1
0.4
Current Ratio 10.20
BIOC's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: 10.20 )
BIOC' s 10-Year Current Ratio Range
Min: 0.02   Max: 10.2
Current: 10.2

0.02
10.2
Quick Ratio 10.09
BIOC's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: 10.09 )
BIOC' s 10-Year Quick Ratio Range
Min: 0.02   Max: 10.09
Current: 10.09

0.02
10.09

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.00
BIOC's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: 2.00 )
BIOC' s 10-Year Price/Net Cash Range
Min: 3.84   Max: 4.49
Current: 2

3.84
4.49
Price/Net Current Asset Value 1.95
BIOC's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: 1.95 )
BIOC' s 10-Year Price/Net Current Asset Value Range
Min: 3.82   Max: 4.39
Current: 1.95

3.82
4.39
Price/Tangible Book 1.73
BIOC's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: 1.73 )
BIOC' s 10-Year Price/Tangible Book Range
Min: 3.5   Max: 3.88
Current: 1.73

3.5
3.88
Earnings Yield (Greenblatt) -262.40
BIOC's Earnings Yield (Greenblatt) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BIOC: -262.40 )
BIOC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 276.6   Max: 685.9
Current: -262.4

276.6
685.9

Business Description

Industry: »
Compare: » details
» More Articles for BIOC

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest volume increases Oct 29 2014
Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells Oct 13 2014
Biocept Expands Collaboration With MD Anderson Cancer Center Oct 07 2014
Biocept to Present at the 13th Annual BIO Investor Forum Sep 30 2014
Biocept Granted Patent in China for Its Microfluidic Channel Technology Used to Capture Circulating... Sep 18 2014
Biocept to Present at Upcoming Investor Conferences Sep 04 2014
Biocept Strengthens Its Circulating Tumor Cell IP Position in Europe Sep 03 2014
BIOCEPT INC Financials Aug 19 2014
Biocept Provides Second Quarter Operational Update Aug 14 2014
BIOCEPT INC Files SEC form 10-Q, Quarterly Report Aug 08 2014
Biocept Appoints Managed Care Expert to Lead Contract and Reimbursement Strategy Aug 06 2014
BIOCEPT INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 24 2014
Exclusive: Biocept's CEO Lays Out This Small Cap's Massive Opportunity Jul 08 2014
BIOCEPT INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... Jun 18 2014
5 Stocks Poised for Breakouts Jun 13 2014
BIOCEPT INC Files SEC form 8-K, Change in Directors or Principal Officers May 23 2014
BIOCEPT INC Files SEC form 10-Q, Quarterly Report May 14 2014
BIOCEPT INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... May 06 2014
BIOCEPT INC Files SEC form 10-K, Annual Report Mar 28 2014
Biocept Appoints Commercialization Leader to Implement Global Diagnostic Sales Program Mar 24 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK